Immunicum seeks approval for a clinical phase I/II-trial in liver cancer

SWEDEN


Press release
130430

Immunicum AB (publ), which develops therapeutic cancer vaccines, initiated a
clinical phase I/II-trial in renal cell carcinoma in February 2012. The Company
has now submitted an application to the Medical Products Agency for
permission to start another clinical phase I/II-trial in liver cancer. The study will
include a total of 12 patients, and is planned in cooperation with the
Transplantation Centre at Sahlgrenska University Hospital in Gothenburg,
Sweden, where Dr Magnus Rizell is responsible for the trial. The first patient
is expected to be included around the turn of 2013/2014.

- The application has been submitted according to plan and we look forward
to starting our second clinical trial. We believe our vaccine, INTUVAX, has
potential to help the large number of liver cancer patients that are not
diagnosed early enough to possibly be cured by transplantation or surgery,
says Jamal El-Mosleh, CEO of Immunicum.

Immunicum’s patented vaccine is based on over 30 years of research in the
field of transplantation immunology and activates the body's own immune
system to attack harmful substances like tumor cells. The Company has
recently completed two new share issues, bringing in a total of 30.2 million
SEK before issue costs. The shares have been traded since April 22, 2013 at
NASDAQ OMX First North under the ticker IMMU.

G&W Fondkommission is chosen as the Company’s Certified Adviser.
Tel: +468-503 000 50. www.gwkapital.se.

For further information please contact:
Jamal El-Mosleh, CEO of Immunicum, 0703-31 90 51,
jamal.elmosleh@immunicum.com

About Immunicum AB (publ):

Immunicum AB (publ) develops cancer immunotherapies. Its two main groups
of therapeutic cancer vaccines, SUBCUVAX™ and INTUVAX™, and the
method of expansion of tumor-specific T-cells (CD70) is based on the Nobel
prize awarded discovery of the dendritic cell and its central role in the
activation of the specific immune response. Because the raw material consists
of dendritic cells from healthy donors, Immunicum’s products can be produced
in large scale. The vaccines have earlier proven efficacy in animal studies and
are now undergoing clinical trials in patients.

 

 


Attachments

Press release 130430 - HCC-application to the MPA.pdf